250 related articles for article (PubMed ID: 2003707)
1. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group.
Gelber RD; Goldhirsch A; Cavalli F
Ann Intern Med; 1991 Apr; 114(8):621-8. PubMed ID: 2003707
[TBL] [Abstract][Full Text] [Related]
2. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle.
Ludwig Breast Cancer Study Group
N Engl J Med; 1988 Sep; 319(11):677-83. PubMed ID: 2901037
[TBL] [Abstract][Full Text] [Related]
3. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
Gelber RD; Goldhirsch A
J Clin Oncol; 1986 Dec; 4(12):1772-9. PubMed ID: 3783203
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
Goldhirsch A; Gelber R
NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
[TBL] [Abstract][Full Text] [Related]
7. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer.
Ludwig Breast Cancer Study Group
N Engl J Med; 1989 Feb; 320(8):491-6. PubMed ID: 2644533
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P
Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056
[TBL] [Abstract][Full Text] [Related]
9. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
[TBL] [Abstract][Full Text] [Related]
10. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
11. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
Goldhirsch A; Gelber RD; Simes RJ; Glasziou P; Coates AS
J Clin Oncol; 1989 Jan; 7(1):36-44. PubMed ID: 2642538
[TBL] [Abstract][Full Text] [Related]
12. International Breast Cancer Study Group trials.
Coates A
Recent Results Cancer Res; 1998; 152():429-40. PubMed ID: 9928577
[TBL] [Abstract][Full Text] [Related]
13. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Camoriano JK; Loprinzi CL; Ingle JN; Therneau TM; Krook JE; Veeder MH
J Clin Oncol; 1990 Aug; 8(8):1327-34. PubMed ID: 2199619
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival.
Gelber RD; Cole BF; Goldhirsch A; Bonadonna G; Howell A; McArdle CS; Mouridsen HT; Rubens RD; Welvaart K
Cancer J Sci Am; 1995; 1(2):114-21. PubMed ID: 9166464
[TBL] [Abstract][Full Text] [Related]
19. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
Falkson HC; Gray R; Wolberg WH; Gillchrist KW; Harris JE; Tormey DC; Falkson G
J Clin Oncol; 1990 Apr; 8(4):599-607. PubMed ID: 2179477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]